Gilead Sciences CFO insider stock sale disclosed on Form 4

Rhea-AI Filing Summary

Gilead Sciences, Inc. (GILD) reported an insider transaction by its Chief Financial Officer. On 11/17/2025, the CFO sold 2,500 shares of Gilead common stock at a price of $125.23 per share in an open-market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 154,555 shares of Gilead common stock in direct ownership. The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, which is designed to allow insiders to trade according to predetermined instructions.

Insider Trade Summary

Net Seller: 2,500 shares ($313,075)

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 2,500 shs ($313K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$125.23	$313K

Holdings After Transaction: Common Stock — 154,555 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		2,500	D	$125.23	154,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Gilead Sciences (GILD) disclose in this Form 4?

The filing reports that the Chief Financial Officer of Gilead Sciences, Inc. sold 2,500 shares of Gilead common stock on 11/17/2025 in an open-market transaction coded as an "S" sale.

At what price were the Gilead (GILD) shares sold in the reported transaction?

The 2,500 shares of Gilead common stock were sold at a price of $125.23 per share.

How many Gilead (GILD) shares does the CFO own after this Form 4 transaction?

Following the reported sale, the CFO beneficially owns 154,555 shares of Gilead common stock, held in direct ownership.

Was the Gilead (GILD) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Who is the reporting person in this Gilead Sciences (GILD) Form 4?

The reporting person is an officer of Gilead, serving as Chief Financial Officer. The signature block reflects execution by /s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson.

Is this Gilead (GILD) Form 4 filed by more than one reporting person?

No. The form indicates that it is filed by one reporting person, not a group filing.